Neumoloxía
Servizo
Imperial College London
Londres, Reino UnidoPublicacións en colaboración con investigadores/as de Imperial College London (8)
2022
2021
-
EAACI Biologicals Guidelines—Recommendations for severe asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44
2020
-
Characteristics and treatment regimens across ERS SHARP severe asthma registries
European Respiratory Journal, Vol. 55, Núm. 1
-
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057
-
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1023-1042
-
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068
2017
-
Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease
Journal of the American Medical Directors Association, Vol. 18, Núm. 12, pp. 1097.e11-1097.e24